A study of chemotherapy relative dose intensity in colon cancer patients at Sunpasitthiprasong hospital
Article Sidebar
Main Article Content
Abstract
Colon cancer has a high incidence and mortality. Chemotherapy has been shown to increase response rate and survival. Relative dose intensity (RDI) is an important factor to determine chemotherapy efficacy. This research was aimed to evaluate the median of relative dose intensity (median RDI) in colon cancer patients who received chemotherapy. Methods: A retrospective cohort study was conducted in colon cancer patients who received chemotherapy at Sunpasitthiprasong hospital during January 1st, 2017 – December 31st, 2017. Descriptive statistics were applied to report a median RDI. Overall survival rate (OS) among patients who received high relative dose intensity greater than or equal to 80% (high-RDI) versus low relative dose intensity less than 80% (low-RDI) were compared using log-rank test. Simple linear regression was performed to analyze a relationship between RDI and hematologic parameters. SPSS version 26.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analysis and data management. Results: Ninety colon cancer patients were enrolled. Majority of patients were male (56.7%) with mean age at diagnosis of 61.12 ± 12.42 years old. of which 73.4% of patients were at early stage of colon cancer. A median RDI of chemotherapy was 81.32%± 24.79. Of which 53.33 of patients were at high-RDI group. A significant improvement of 1-year OS was seen in patients who were treated with high-RDI (97.87% vs 78.94%, p<0.001). A relationship between high RDI and hematologic suppression were not detected. Conclusion: This study demonstrated that a median RDI was 81.32% among colon cancer patients being treat at Sunpasitthiprasong hospital. Chemotherapy with high-RDI improved overall survival rate without increasing of hematologic toxicities.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Alberto P. Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity. Bull Cancer 1995; 82(1): 3s-8s.
Andre T, Boni C, Navarro M, et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 2004; 350: 2343-2351.
Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
Aspinall SL, Good CB, Zhao X, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC center 2015; 15: 62.
Blazevic I, Vaillant W, Basso W, et al. Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer. Contemp Oncol (Pozn) 2020; 24(3): 150-156.
Bylsma LC, Nielson CM, Fryzek JP, et al. Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis. Blood 2020; 136 (Supplement 1): 32–33.
De Gramont A, Bosset JF, Milan C, et al. Randomized Trial Comparing Monthly Low-Dose Leucovorin and Fluorouracil Bolus with Bimonthly High-Dose Leucovorin and Fluorouracil Bolus Plus Continuous Infusion for Advanced Colorectal Cancer: A French Intergroup Study. J Clin Oncol 1997; 15(2): 808-815.
De Gramont A, Figer A, Seymour M, et al. Leucovorin and Fluorouracil with or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2000; 18(16): 2938-2947.
Health Administration Division. Public Health Statistics A.D. 2019. Nonthaburi: Ministry of public health; 2019.
Jie Y, Xiaohan Y, Xiaoling Z, et al. Impact of dose intensity of first-line chemotherapy on prognosis of patients with metastatic colorectal cancer. Tumor 2017; 37(3): 255-261.
Lakkunarajah S, Breadner DA, Ahang H, et al. The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis. Curr Oncol 2021; 28: 4031–4041.
Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorinand 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 2000; 11: 1477-1483.
Nakayama G, Tanaka C, Uehara K, et al. The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemother Pharmacol 2014; 73(4): 847–855.
National Cancer Institute. Medical Record and Databased Cancer Unit, 2021; Bangkok, Thailand.
National Cancer Institute. Medical Record and Databased Cancer Unit, 2020; Bangkok, Thailand.
National comprehensive cancer network. NCCN clinical practice guidelines in oncology (NCCN guideline) Colon cancer version 2.2021 [internet]. 2021 [cited 2021 Feb 26]. Available from https://www.nccn.org/ professionals/physician_gls/pdf/colon.pdf.
Nielson CM, Bylsma LC, Fryzek JP, et al. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis. The Oncologist 2021; 26: e1609–e1618.
Zhou M, Thompson TD, Chen VW, et al. Impact of elative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. Clin Colorectal Cancer 2021; 1(35): 1-14.